EB2 NIW RFE Response That Met USCIS Expectations
Ascend recently observed another successful approval of an EB2-NIW petition for one of our distinguished clients on July 23, 2025. This marked the culmination of an intense, meticulously executed process led by our specialized RFE Division. This EB2 NIW RFE success story is not just about securing an approval. It reflects extraordinary perseverance, strategic thinking, and legal expertise demonstrated through a well-planned national interest waiver visa strategy. Moreover, it also shows a precise response to a challenging Request for Evidence.
Timeline of Key Milestones
February 5, 2025: The petition, initially prepared by our team under the EB2 national interest waiver visa category, was dispatched to USCIS. February 14, 2025: USCIS received the petition on Valentine’s Day and issued the receipt notice under Premium Processing. April 3, 2025: The unexpected challenge arrived: USCIS issued a detailed Request for Evidence (RFE), questioning crucial aspects of the case. This EB2 NIW RFE case was immediately assigned to Ascend’s dedicated RFE division, under the strategic leadership of Vishesh Kumar and handled by Bhimesh Singh. June 27, 2025: After rigorous research and documentation, the comprehensive response to the Request for Evidence was finalized and filed. July 1, 2025: USCIS confirmed receipt of the RFE response. July 23, 2025: Victory was achieved when USCIS issued the EB2-NIW approval, bringing closure to a demanding national interest waiver visa journey.The Case and Its Challenges
Our client, a Quality Assurance (QA) Manager in a reputed pharmaceutical company, had an impressive background, playing a key role in ensuring compliance and quality control for a life-changing GLP-1 solution for weight management. This therapeutic advancement carries national significance given the growing obesity epidemic in the United States. Above all, this is a core consideration under the national interest waiver visa framework. However, the request for evidence posed significant hurdles, questioning the national importance of the client’s contributions, the extent of her influence, and her well-positioned status to advance her proposed endeavor in the U.S. This is where Ascend’s RFE Division stepped in. Under the guidance of our Team at Ascend, the RFE Division took ownership of the case and navigated every nuance with precision. Recognizing that USCIS demanded a higher evidentiary threshold following the EB2 NIW RFE. The drafting went beyond a conventional approach. Our team conducted in-depth research into pharmaceutical QA systems, FDA audit compliance frameworks, and emerging GLP-1 therapeutic trends.The Strategy Behind the EB2 NIW RFE Win
Our strategy was built on two critical pillars:Firstly, strengthening the national interest narrative. By aligning the client’s QA work with U.S. healthcare priorities, combating obesity, and ensuring pharmaceutical safety, the team demonstrated substantial merit. Her contributions carried national importance. This approach utilized the Matter of Dhanasar framework, a key standard for the national interest waiver visa.
Secondly, utilising authoritative endorsements. To address concerns raised in the Request for Evidence regarding influence and impact, Ascend secured high-impact recommendation letters. These included one from a Nobel Prize-winning scientist and several from FDA experts. These endorsements established the significance of the client’s work in enabling large-scale pharmaceutical compliance and safeguarding public health.
Additionally, we incorporated legal arguments on QA workforce shortages highlighted by GAO reports. We demonstrated how the client’s internal mentorship initiatives would bridge critical gaps in U.S. quality assurance talent pipelines, an angle that resonated strongly with USCIS evaluators.The Team Effort and Leadership
While drafting and legal research were central to this case, the success also reflected the collaborative spirit at Ascend. The team provided strategic oversight to ensure every submission met the highest legal and procedural standards. The entire process was orchestrated under the leadership of Vasanthan Ramakrishnan, CEO of Ascend HSI Partners. His commitment to excellence and client-first philosophy continues to shape Ascend’s success in complex national interest waiver visa matters.
Going the Extra Mile
What truly set this case apart was the unwavering dedication of the RFE Division. From late-night strategy calls to early-morning drafting sessions, the team demonstrated what it means to go above and beyond. Their ability to translate complex technical concepts into compelling legal arguments, combined with a meticulous response to the Request for Evidence, was impressive. In other words, this approach transformed a challenging situation into a strong approval.
An interesting highlight was the extraordinary step Ascend took to secure letters from the CDC and the FDA. Eventually, this move amplified the credibility of the client’s profile. This reinforced the case as a clear example of merit under the national interest waiver visa. Ultimately, it resolved the remaining concerns raised in the EB2 NIW RFE.The Outcome
On July 23, 2025, when the approval notice arrived, it wasn’t just a win for the client. It was a victory for meticulous planning, teamwork, and legal craftsmanship. The client can now confidently continue her impactful work in the U.S., advancing pharmaceutical quality standards and contributing to national health priorities. At Ascend, this success reinforces our belief that every RFE is an opportunity to excel, innovate, and deliver beyond expectations. And at the heart of this success story stands our team from the RFE Division. Their efforts on this case exemplify the core values of Ascend’s dedication, precision, and results.
WE CAN HELP